[PHARMANIAGA BHD：印度尼西亚部门的需求增加]

2Q19 vs 2Q18:
截至2019年6月30日的第二季度，集团录得收入6.02亿令吉，较去年同期的5.83亿令吉增长3.3％。这主要是由于印度尼西亚部门的需求增加。尽管营销和促销费用增加以及融资成本增加，该集团的税前利润（PBT）为1200万令吉，比去年同期增长4.3％。因此，加上较低的企业税支出，集团在这季的税后利润（PAT）改善到900万令吉，而去年同期为500万令吉。

YTD19 vs YTD18：
这财政年度的头六个月，集团实现了14亿令吉的收入，而去年同期为12亿令吉。这是在特许和非特许业务均取得强劲业绩的背景下实现的。尽管贡献毛利率减少和融资成本增加，但集团的PBT增长5％至4,300万令吉。因此，加上较低的企业税开支，集团录得2,900万令吉的PAT，高于去年同期的2,300万令吉。

物流与分销部：该部门在六个月期间录得较高的PBT 1900万令吉，与去年同期的900万令吉相比增长了两倍。尽管运营成本增加，但非特许业务的贡献增加推动了业绩的改善。

制造部门：该部门的税前利润为2800万令吉，略低于去年同期的3400万令吉。

印尼部门：该部门的PBT为10万令吉，低于去年同期的120万令吉。

2Q19 vs 1Q19：
这季度的PAT较低，为900万令吉，较上一季度的2,000万令吉有所下降。

前景：
长期而言，这集团有信心医疗行业的前景良好。 Pharmaniaga随时准备利用增长机会来扩展产品组合，以通过研发驱动来满足不断变化的医疗保健需求。此外，战略性营销举措将使集团能够加强其在私营部门的立足点。

同时，这集团继续扩大其全球业务，特别在印尼仍是一个关键的增长领域。这集团亦继续专注于持续改善其业务，以确保更高的效率及成本优化，以推动Pharmaniaga的可持续增长。
-----------------------------
James Ng Stock Pick Performance:
Since Recommended Return:

a) FRONTKN (FRONTKEN CORP BHD), recommended on 12 Aug 18, initial price was RM0.715, rose to RM1.91 (dividend RM0.025) in 1 year 2 months 19 days, total return is 170.6%

b) PRLEXUS (PROLEXUS BHD), recommended on 25 Aug 19, initial price was RM0.455, rose to RM0.915 in 2 months 6 days, total return is 101.1%

c) JAKS (JAKS RESOURCES BHD), recommended on 20 Jan 19, initial price was RM0.575, rose to RM1.06 in 9 months 11 days, total return is 84.3%

d) KKB (KKB ENGINEERING BHD), recommended on 1 Jul 18, initial price was RM0.795, rose to RM1.39 (dividend RM0.04) in 1 year 3 months 29 days, total return is 79.9%

e) GBGAQRS (GABUNGAN AQRS BHD), recommended on 16 Dec 18, initial price was RM0.80, rose to RM1.29 in 10 months 15 days, total return is 61.3%

f) KGB (KELINGTON GROUP BHD), recommended on 23 Dec 18, initial price was RM0.965, rose to RM1.37 (dividend RM0.018) in 10 months 8 days, total return is 43.8%

g) PWROOT (POWER ROOT BHD), recommended on 7 Oct 18, initial price was RM1.59, rose to RM2.18 (dividends RM0.083) in 1 Year 24 days, total return is 42.3%

h) ELKDESA (ELK-DESA RESOURCES BHD), recommended on 18 Nov 18, initial price was RM1.27, rose to RM1.73 (dividend RM0.07) in 11 months 13 days, total return is 41.7%

i) MI (MI TECHNOVATION BERHAD), recommended on 2 Jun 19, initial price was RM1.67, rose to RM2.31 (dividend RM0.01) in 4 months 28 days, total return is 38.9%

j) BAUTO (BERMAZ AUTO BHD), recommended on 14 Oct 18, initial price was RM1.89, rose to RM2.28 (dividend RM0.22) in 1 Year 17 days, total return is 32.3%

k) PESTECH (PESTECH INTERNATIONAL BHD), recommended on 2 Jun 19, initial price was RM1.04, rose to RM1.28 in 4 months 28 days, total return is 23.1%

l) DESTINI (DESTINI BHD), recommended on 24 Sep 19, initial price was RM0.20, rose to RM0.23 in 1 months 7 days, total return is 15%

m) SERBADK (SERBA DINAMIK HOLDINGS BHD), recommended on 29 Jul 18, initial price was RM3.96, rose to RM4.17 (dividends RM0.111) in 1 Year 3 months 2 days, total return is 8.1%

n) BJFOOD (BERJAYA FOOD BHD), recommended on 30 Sep 18, initial price was RM1.43, rose to RM1.49 (dividends RM0.04) in 1 Year 1 month 1 day, total return is 7%

我希望将我的策略分享给读者，希望他们在阅读后能够表现出色。我正在使用基本面分析（Fundamental Analysis）：

预计公司每年的增长率必须> 14％

我想说服读者学习基本面分析FA以便能从股市赚钱。

我为想从马来西亚股票市场赚钱的读者提供STOCK PICK服务。想订阅我的邮件以从股票市场获取良好回报的人，可以通过jamesngshare@gmail.com 或我的FB页面与我联系。

1)【看懂年报和季报】课程:
11a.m. – 7p.m.，免费茶和咖啡

12月22日星期日：AG Hotel Penang, George Town 2份点心

12月29日星期日：Hotel Sri Petaling, KL 3份点心

2020年2月22日星期六：Silka Johor Bahru Hotel, Johor Bahru 7份点心

2)【股票-实际操作班】课程：
10a.m. – 9p.m.，免费午餐和晚餐

12月21日星期六：AG Hotel Penang, George Town

12月28日星期六：Hotel Sri Petaling, KL

2020年2月23日星期日：Silka Johor Bahru Hotel, Johor Bahru

3) 【公司业绩分享会】:
2p.m. – 7p.m.，免费茶和咖啡

12月20日星期五：AG Hotel Penang, George Town 2份点心

12月27日星期五：Hotel Sri Petaling, KL 3份点心

2020年2月21日星期五：Silka Johor Bahru Hotel, Johor Bahru 7份点心

有兴趣的朋友，可以电邮或PM FB page联络我
email：jamesngshare@gmail.com
电话/Whatsapp : 011 - 15852043

Facebook Group: https://www.facebook.com/groups/jamesinvesting

这个是我的TELEGRAM Group链接，大家可以在这个Group获知何时做Fb live: https://t.me/joinchat/LhwHNhdU1fDgxrSafTrTiw

请大家来Follow James的Instagram，获取最新的资讯：jamesnginvest

这个分享纯属讨论以及领域的分析，买或卖自负。请Like和Share这个post。最终决定永远是你的，谢谢。

James Ng
---------------------------
[PHARMANIAGA BHD: stronger demand under the Indonesia Division]

2Q19 vs 2Q18:
For the second quarter ended 30 June 2019, the Group recorded a revenue of RM602 million, up by 3.3% compared with RM583 million in the previous year’s corresponding quarter. This was mainly attributable to stronger demand under the Indonesia Division. The Group registered a profit before tax (PBT) of RM12 million, a 4.3% increase from last year’s corresponding quarter despite increased marketing and promotional expenses as well as higher finance costs. Accordingly, coupled with lower corporate tax expense, the Group delivered an improved profit after tax (PAT) of RM9 million for the quarter under review, compared with RM5 million in the previous year’s corresponding quarter.

YTD19 vs YTD18:
For the first six months of the financial year under review, the Group delivered a higher revenue of RM1.4 billion compared with RM1.2 billion in the same period last year. This was achieved on the back of strong performances from both the concession and non-concession businesses. This saw the Group's PBT increase by 5% to RM43 million, despite reduced contribution margins and higher finance costs. As a result of this coupled with lower corporate tax expense, the Group recorded a higher PAT of RM29 million compared with RM23 million in the same period last year.

Logistics and Distribution Division: The division recorded a higher PBT of RM19 million for the six-month period, reflecting a two-fold increase compared with RM9 million in last year’s corresponding period. Despite higher operating costs, the improved performance was driven by better contributions from the non-concession business.

Manufacturing Division: The division posted a PBT of RM28 million, slightly lower than RM34 million in the same period last year.

Indonesia Division: The division turned in a lower PBT of RM0.1 million compared with RM1.2 million in the same period last year.

2Q19 vs 1Q19:
PAT for the quarter under review was lower at RM9 million, a drop from RM20 million in the immediate preceding quarter.

Prospects:
Over the long-term, the Group is confident that prospects for the healthcare industry are positive. Pharmaniaga is poised to tap into opportunities for growth as it expands its product portfolio to cater to evolving healthcare needs via its research and development drive. Moreover, strategic marketing initiatives will enable the Group to reinforce its foothold in the private sector.

In tandem, the Group continues to stepup its global presence, particularly in Indonesia which remains a key growth area. The Group also remains focused on continuous enhancements in its operations to ensure greater efficiency and cost optimisation, in order to propel the sustainable growth of Pharmaniaga.
--------------------------------------------------------------------------
I wish to share my strategy to readers, hope that they can perform well after reading this. I am using Fundamental Analysis:

the forecasted growth of a company must > 14% per year

I wish to convince readers to learn FA in order to make money from stock market.

I am providing STOCK PICK SERVICE for readers who want to make money from Malaysian stock market. Those who want to subscribe to my mailing list to achieve a good return from stock market, you can contact me at jamesngshare@gmail.com or PM me in my FB page.

This sharing is purely a discussion and analysis of the sector, buying or selling at your own risk. Please Like and Share this post. Final decision is always yours, thank you.

James Ng